Ask The Experts: The Evolution of Immune Checkpoint Inhibitors to Treat Lung Cancer and Melanoma
Immune checkpoint inhibition continues to evolve as standard therapy for a growing number of solid and hematologic malignancies including melanoma and lung cancer. This educational activity will discuss the pathophysiology and evolution of immune checkpoint inhibitors and analyze recent survival and toxicity data for managing patients with melanoma and lung cancer. Additionally, identification of biomarkers to optimize immune checkpoint inhibitor selection will be explored.
Learning Objectives
- Define the pathophysiology of immunotherapy and the evolution of immune checkpoint inhibition.
- Analyze recent immune checkpoint inhibitor survival and toxicity data and apply to the therapy management of patients with melanoma and lung cancer.
- Identify established and emerging biomarkers to optimize selection of immune checkpoint regimens for patients with melanoma and lung cancer.
- Describe interprofessional education strategies for patients and caregivers on the safety and monitoring of immune checkpoint inhibitors.
Faculty
Christine M. Walko, Pharm.D., BCOP, FCCP, Activity Chair
Associate Member, Department of Individualized Cancer Management
Moffitt Cancer Center
Tampa, Florida
.jpg)
Shetal Patel, M.D., Ph.D.
Assistant Professor of Medicine
Division of Hematology/Oncology
UNC School of Medicine
Chapel Hill, North Carolina
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of lung cancer and melanoma patients with immunotherapies.
Format
This online activity consists of slide presentations, active learning, and an evaluation. View the system requirements.
Disclosures
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individual/s below has disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
Christine M. Walko, Pharm.D., BCOP, FCCP
- Consultant for Jackson Genetic Laboratories
Shetal A. Patel, M.D., Ph.D.
- AstraZeneca: Principle Investigator
Claim CE Within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to complete the assessment and evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
CPE Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #: 0204-000-19-412-H01-P
Release Date: May 13, 2020
Expiration Date: May 13, 2021
Activity Type: Application-based
CE Credits: 1.0 hour
Activity Fee: Free of charge
CME Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.